PHGE — BiomX Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1739174 ·
Last close
$0.23
Market Cap
$2.74M
52W High
$2.96
52W Low
$0.21
ADV30
4,330,825
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,296,000 | -19,140,000 | 3,251,000 | 1,168,000 | 4,132,000 |
| Dec 2025 | 0 | — | -7,195,000 | -13,337,000 | 5,783,000 | 4,360,000 | 7,085,000 |
| Sep 2025 | 0 | — | -8,536,000 | -9,166,000 | 26,168,000 | 6,923,000 | 15,682,000 |
| Jun 2025 | 0 | — | -7,433,000 | -6,037,000 | 38,050,000 | 14,046,000 | 18,890,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,092,000
Investing CF
$-939,000
Financing CF
$3,899,000
CapEx
$-21,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-22.77
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-236,036,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-48,188,000
Pretax Income TTM
$-47,674,000
Interest Exp TTM
$-514,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -30,920,000 | -36,199,000 | 5,783,000 | 7,085,000 | — | -26,390,000 |
| Dec 2024 | 0 | -35,551,000 | -17,727,000 | 43,233,000 | 19,085,000 | — | -36,979,000 |
| Dec 2023 | 0 | -25,348,000 | -26,169,000 | 25,029,000 | 21,948,000 | — | -21,286,000 |
| Dec 2022 | 0 | -27,219,000 | -28,317,000 | 45,531,000 | 24,492,000 | — | -29,092,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.01
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | $2.72M | $0.14 | — |
| SLXN | Silexion Therapeutics Corp | $2.75M | $2.59 | — |
| VIVS | VivoSim Labs, INC. | $2.54M | $0.88 | — |
| APTOF | Aptose Biosciences Inc. | $4.31M | $1.69 | — |
| OPTEY | Opthea Ltd | $4.62M | $0.03 | — |
News headlines (Yahoo Finance, 1h cache)
BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities
2026-07-10 11:25 · Yahoo
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure
2026-07-08 11:05 · Yahoo
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement
2026-07-06 12:32 · Yahoo
BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026
2026-06-24 12:38 · Yahoo
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy
2026-06-18 13:15 · Yahoo
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance
2026-06-12 13:00 · Yahoo
BiomX: Zorronet’s AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events
2026-06-11 13:03 · Yahoo
Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit
2026-06-02 13:32 · Yahoo
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
2026-06-01 13:25 · Yahoo
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
2026-05-27 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.